PHAXIAM Therapeutics S.A.

Equities

PHXM

FR001400K4B1

Biotechnology & Medical Research

End-of-day quote Euronext Paris 06:00:00 2024-06-10 pm EDT 5-day change 1st Jan Change
2.875 EUR +0.17% Intraday chart for PHAXIAM Therapeutics S.A. +0.35% -37.50%
Chart PHAXIAM Therapeutics S.A.
More charts
PHAXIAM Therapeutics S.A. is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, responsible for many serious infections. The company relies on an innovative approach based on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics S.A. is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
Calendar
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.1 EUR
Average target price
7.05 EUR
Spread / Average Target
+235.71%
Consensus
  1. Stock Market
  2. Equities
  3. PHXM Stock
  4. News PHAXIAM Therapeutics S.A.
  5. Phaxiam Therapeutics Delists from Nasdaq Capital Market